Xenopat, a member of CataloniaBio, is one of the six entrepreneurship projects in the healthcare arena to be selected for the UnLtd Spain and Lilly Emprende inHealth programme. This means they will receive training, guidance, mentoring and the opportunity to participate in networking activities over eight months. It also comes with €5,000 in seed capital to help make the start-up a sustainable business.

Xenopat, headed up by Anna Portela, is addressing the need to design personalised oncology treatments. The company currently has model mice, Orthoxenograft®, which can be created for each patient in order to personalise their cancer treatment, cutting the time and cost of taking new drugs to market. They also help limit the number of ineffective and unnecessary treatments administered. 

The other projects selected are MJN, Anapphylaxis, Fiixit, Werium and MyLeaf.